SXTP
60 DEGREES PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.97
−4.29%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.95
From 52W high−81.41%
Volume36912.00
Market cap$3.40M
P/E (TTM)—
P/S (TTM)3.1x
Div yield—
Key dataNov 4, 2026
Open
$0.95
From 52W high
−81.41%
Volume
36912.00
Market cap
$3.40M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.5x
P/E (TTM)
—
RSI (14)
49.5
MomentumView details →
1D Return
−4.29%
YTD Return
−53.20%
SummaryUpdated Jun 1, 2026
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) is a specialty pharmaceutical company founded in 2010 and headquartered in Washington, D.C. The company went public in July 2023 and focuses on developing and commercializing therapies for the prevention and treatment of infectious diseases. Since its IPO, the company has experienced significant stock price volatility, declining from over $16 per share in 2023 to around $2 per share currently, reflecting the challenges typical of early-stage biotech companies with limited commercial revenue.
Similar companies
Latest newsMore news →
60 DEGREES PHARMACEUTICALS, INC. announced a sponsored research agreement with University of Southern Mississippi to evaluate castanospermine in nonclinical models of alpha-gal syndrome.7d ago60 DEGREES PHARMACEUTICALS, INC. reported clinical and molecular results for the first five patients to complete treatment in its expanded-access study of relapsing babesiosis; all five reported being much or very much improved and had negative conventional PCR results for Babesia.8d ago60 Degrees Pharmaceuticals announced it will conclude enrollment in its randomized clinical study of tafenoquine in hospitalized babesiosis patients, with primary and secondary endpoint results expected in January 2027.29d ago